Dulpatatug

LUND, SE / ACCESS Newswire / May 22, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today comments on a recent update shared by Shanghai Henlius Biotech, Inc. regarding long-term follow-up observations from clinical studies of HLX22. According to Henlius' communication, long-term follow-up over more than 39 months indicates that patients treated with HLX22 continue to demonstrate extended progression-free survival (PFS) at the current observation point. The update reflects ongoing follow-up and does not include new numerical efficacy data. HLX22 is an innovative anti-HER2 monoclonal antibody that has been granted orphan drug designation in both the U.S. and EU for gastric cancer and is being developed by Henlius under a license from AbClon, Inc., following a discovery collaboration which grants Alligator the right to participate in potential future revenues. "We view Henlius' update on the long-term follow-up of HLX22 as further evidence of the continued clinical development of the program," said Søren Bregenholt, CEO of Alligator Bioscience . "Sustained follow-up across studies is an important part of building the overall understanding of a molecule's profile, and we note Henlius' ongoing efforts to advance HLX22 across multiple indications." Under the terms of Alligator's agreement with AbClon, Alligator is entitled to 35% of AbClon's revenue from its sublicense to Henlius, including potential milestone payments and royalty revenues, which, if HLX22 is successfully developed and approved, could represent a meaningful long-term revenue opportunity for Alligator. For further information, please contact: Søren Bregenholt, CEO E-mail: soren.bregenholt@alligatorbioscience.com Phone: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 08:15 a.m. CEST on 22 May 2026. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently ready for Phase 3 development, and has previously presented unprecedented survival data at 30-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit alligatorbioscience.com . Attachments Alligator Bioscience comments on Henlius update on long-term follow-up data for HLX22 SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire

Mitazalimab momentum: Final OPTIMIZE‑1 outcomes were presented at ASCO GI 2026, with additional investigator‑initiated data accepted for AACR 2026. External portfolio progress: The first patient was dosed in Henlius’ Phase 2/3 study of HLX22 in recurrent breast cancer. Capital structure update: The TO 14 warrant program was completed in line with previously communicated terms, with gross proceeds of approx. 19 MSEK. LUND, SE / ACCESS Newswire / May 5, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced its interim results for the first quarter of 2026 and provided a business update. "During the first quarter of 2026, we continued to execute against our strategic priorities in a challenging biotech environment. We strengthened the clinical and translational foundation of mitazalimab through new data presentations, while maintaining clear focus on advancing the program toward late‑stage development under disciplined strategic and financial conditions. In parallel, HLX22 progress in our external portfolio, supports additional long‑term value potential without development cost exposure for Alligator." Søren Bregenholt, CEO of Alligator Bioscience BUSINESS UPDATE Mitazalimab Additional data dissemination: Updated and final outcomes data from the OPTIMIZE 1 study were presented at the ASCO Gastrointestinal Cancers Symposium 2026, further strengthening the clinical and translational foundation of the program. Continued scientific visibility: New data from an investigator initiated trial evaluating mitazalimab were accepted for presentation at the AACR Annual Meeting 2026, providing additional insight into the antibody's mechanism of action and tumor directed immune activation. Technology Strengthened intellectual property position: Alligator strengthened the intellectual property protection for its bispecific antibody technology RUBY™, reinforcing the scientific and commercial foundation for future pipeline development and partnering opportunities. HLX22 Progress in partnered development: The first patient was dosed in Henlius' Phase 2/3 study of HLX22 in recurrent breast cancer, marking an additional step in the late stage development of the program. Company / Financial position Capital structure updates following the rights issue: Alligator announced the outcome of the exercise of warrants of series TO 14, resulting in gross proceeds of approximately 19 MSEK and changes in the number of shares and votes, as well as related directed issues to guarantors and Fenja Capital, in accordance with previously communicated terms. Alligator's management further announced their intention to subscribe pro rata in the TO 14 warrant program, aligning management interests with those of shareholders. Nomination Committee proposal ahead of the AGM: The Nomination Committee presented its proposal for the Board of Directors ahead of the Annual General Meeting, including the nomination of two new Board members. FINANCIAL SUMMARY FOR Q1 2026 The financial summaries for the quarterly periods ending 31 March 2026 and 31 March 2025 are presented below. All amounts in MSEK, unless specified January - March 2026 January - March 2025 Net sales - - Operating profit/loss -17.8 -43.7 Profit/loss for the period 1.4 -8.3 Cash flow for the period -29.1 -34.6 Cash and cash equivalents 33.0 28.9 Earnings per share before and after dilution*, SEK 0.0 -1.1 * Adjusted for reverse share split in 2025. The full report is attached as a PDF, and is also available on the company's website: Alligator will host a webinar on Tuesday, 5 May 2026, at 1 p.m. CEST/ 7 a.m. EDT for investors, analysts and media, where CEO Søren Bregenholt and CFO Johan Giléus will present and comment on the interim report, which will be followed by a Q&A session. The call will be held in English. Attendees need to register by following >>this link<< . For further information, please contact: Søren Bregenholt, CEO E-mail: soren.bregenholt@alligatorbioscience.com Phone: +46 (0) 46 540 82 00 Johan Giléus, CFO E-mail: johan.gileus@alligatorbioscience.com Phone: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 8:00 a.m. CEST on 5 May 2026. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently ready for Phase 3 development, and has previously presented unprecedented survival data at 30-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit alligatorbioscience.com . Attachments 2026 Q1 EN VF SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire